Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
The present invention includes compositions and methods for the treatment of Th1 and/or Th2 mediated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5, mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease.
1. A method of treating chronic obstructive pulmonary disease (COPD) in a subject, comprising detecting an elevated level of IFN-γ and/or IL-13 and administering an effective amount of chemokine receptor 5 (CCR5) antagonist maraviroc to a subject with elevated levels of IFN-γ and/or IL-13 as compared to normal levels, thereby treating said COPD.
2. The method of claim 1 , wherein said subject is a smoker with COPD.
3. The method of claim 1 , wherein said antagonist specifically binds to CCR5.
4. The method of claim 1 , wherein said antagonist binds to a mammalian CCR5.
5. The method of claim 4 , wherein the mammalian CCR5 is a human CCR5.
6. The method of claim 1 , wherein said antagonist inhibits binding of one or more chemokines selected from the group consisting of MIP-1α, MIP1β, and RANTES to the receptor.
7. The method of claim 1 , wherein said antagonist inhibits one or more functions associated with binding of said one or more chemokines to the receptor.
8. The method of claim 1 , wherein said COPD is chronic bronchitis.
9. The method of claim 1 , wherein said COPD is emphysema.